Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
BIO CEO & Investor Conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...
Hosted on MSN1mon
Actuate sees 37% cut in risk of death in Phase II pancreatic cancer trial
US-based biopharma, Actuate Therapeutics’s elraglusib reduced the risk of death by 37% in a Phase I/II metastatic pancreatic cancer trial. The randomised Phase I/II trial (NCT03678883 ...
Wall Street Journal22d
Actuate Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Investing6d
Actuate Therapeutics Inc (ACTU)
CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a biopharmaceutical company with a market capitalization of $161.72 million, announced today that the... ByInvesting.com ...